250+
mock exams
41,634
tests completed
6,39,666
questions answered
The Sree Chitra Tirunal Institute for Medical Sciences and Technology () has unveiled 'Chitra Core,' an indigenously developed coronary stent. The institute has also developed a second stent, 'Chitra TiN,' which is a cutting-edge Titanium Nitride-coated bare metal stent currently undergoing pre-clinical evaluations. This development marks a significant milestone under the initiative, demonstrating India's growing capacity in high-end medical device manufacturing and commercialization.
The development of Chitra Core and Chitra TiN highlights India's progress in frugal innovation (creating high-quality products at lower costs) within the medical devices sector. 'Chitra Core' is a polymer-coated Everolimus drug-eluting stent (DES) utilizing a Cobalt-Chromium alloy platform. Its patented design features 30-40% less metal content than standard stents, minimizing vessel damage and reducing risks like restenosis (re-narrowing of the artery) and late-stage thrombosis (clot formation). The 'Chitra TiN' stent represents a more advanced polymer-free platform. It utilizes a Titanium Nitride (TiN) coating, a highly robust ceramic material. TiN prevents direct metal contact with blood, mitigating the release of nickel ions, which can cause inflammation. The Department of Science and Technology (DST) supported the Chitra TiN project through its Technical Research Centre. From a UPSC perspective, this is a prime example of successful translational research—moving a prototype from the laboratory to commercial production, highlighting the critical role of institutions like SCTIMST in advancing Atmanirbhar Bharat in healthcare technologies.
The commercial launch of these stents is a success story for the Make in India initiative, aiming to reduce India's heavy reliance on imported medical devices. The Indian medical device industry is highly import-dependent (often cited around 70-80%). Developing indigenous, high-quality alternatives like Chitra Core addresses this vulnerability. The technology transfer from SCTIMST to Invasive Technologies Pvt Ltd. under a formal MoU illustrates effective public-private partnership (PPP) in research and development. The commercialization process requires regulatory clearance, as seen with Invasive Technologies securing manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO). Furthermore, the planned global launch of 'Chitra TiN' necessitates rigorous international pre-clinical testing, emphasizing the high standards required for export competitiveness. This aligns with broader economic goals of boosting domestic manufacturing, creating high-skill jobs, and improving the balance of trade in the healthcare sector.
The availability of affordable, indigenously produced coronary stents is crucial for public health equity. Cardiovascular diseases are a leading cause of mortality in India. The high cost of imported stents often makes life-saving treatments inaccessible to the poorer sections of society. Previous government interventions, such as price capping on stents by the National Pharmaceutical Pricing Authority (NPPA), were steps toward affordability. The development of 'Chitra Core' and 'Chitra TiN' provides a structural solution by offering high-quality alternatives at potentially competitive price points. The reduction of complications like restenosis directly improves patient outcomes and reduces long-term healthcare costs. The regulatory oversight by the CDSCO is critical to ensuring patient safety and device efficacy. UPSC aspirants should connect this development to broader themes of Universal Health Coverage (UHC) and the government's role in fostering an ecosystem that supports both innovation and affordable access to advanced medical care.